Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL3 | Q96JM7 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | AR | P10275 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.37 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | CDK1 | P06493 | 1/20 | 0.36 |
| ▸ | CDK2 | P24941 | 1/20 | 0.36 |
| ▸ | WDR91 | A4D1P6 | 1/20 | 0.36 |
| ▸ | ABL1 | P00519 | 1/20 | 0.35 |
| ▸ | RORC | P51449 | 2/20 | 0.35 |
| ▸ | HPGDS | O60760 | 1/20 | 0.35 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | SMPD3 | Q9NY59 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2479186 | 0.88 | AR (0.50) | ARCDK1CDK2WDR91ABL1 | |
| SCHEMBL17353206 | 0.88 | AR (0.50) | ARCDK1CDK2WDR91ABL1 | |
| SCHEMBL1664480 | 0.84 | SYK (0.44) | L3MBTL3L3MBTL1MAPTCDK2HPGDS | |
| SCHEMBL5795262 | 0.81 | — | — | |
| SCHEMBL1031654 | 0.80 | AR (0.36) | ARRORCNOTUM | |
| SCHEMBL3537362 | 0.80 | MBTD1 (0.57) | L3MBTL3L3MBTL1USP2MBTD1SLC18A3 | |
| SCHEMBL17838713 | 0.80 | L3MBTL3 (0.42) | L3MBTL3L3MBTL1USP2MBTD1GPR119 | |
| SCHEMBL550942 | 0.78 | USP2 (0.55) | L3MBTL3L3MBTL1USP2MAPTLMNA | |
| Hydrochloric Acid SCHEMBL1920820 | 0.78 | MBTD1 (0.55) | L3MBTL3L3MBTL1USP2MBTD1SLC18A3 | |
| SCHEMBL4819092 | 0.78 | L3MBTL1 (0.41) | L3MBTL3L3MBTL1USP2MBTD1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220389009-A1 | SUBSTITUTED 1,6-NAPHTHYRIDINE INHIBITORS OF CDK5 | GFB (ABC), LLC | 2022-12-08 | — | — | US | claimed |
| CN-114761000-A | Substituted 1, 6-naphthyridine inhibitors of CDK5 | 金翅雀生物公司 | 2022-07-15 | — | — | CN | claimed |
| WO-2022011274-A1 | SUBSTITUTED 1,6-NAPHTHYRIDINE INHIBITORS OF CDK5 | GOLDFINCH BIO, INC. (US) | 2022-01-13 | — | — | WO | claimed |
| WO-2021067569-A1 | SUBSTITUTED 1, 6-NAPHTHYRIDINE INHIBITORS OF CDK5 | GOLDFINCH BIO, INC. (US) | 2021-04-08 | — | — | WO | claimed |
| US-20180265467-A1 | PYRAZOLIDINE DERIVATIVES AND RELATED COMPOUNDS | SELVITA S.A. (PL) | 2018-09-20 | — | — | US | claimed |
| EP-3356331-A1 | PYRAZOLIDINE DERIVATIVES AND RELATED COMPOUNDS | Selvita S.A. (PL) | 2018-08-08 | — | — | EP | claimed |
| US-20160222014-A1 | COMPOUNDS FOR REGULATING FAK AND/OR SRC PATHWAYS | ASANA BIOSCIENCES, LLC (US) | 2016-08-04 | — | — | US | claimed |
| WO-2015038417-A1 | COMPOUNDS FOR REGULATING FAK AND/OR SRC PATHWAYS | ASANA BIOSCIENCES, LLC (US) | 2015-03-19 | — | — | WO | claimed |
| US-8367673-B2 | Substituted diketopiperazines as oxytocin antagonists | GLAXO GROUP LIMITED (GB) | 2013-02-05 | — | — | US | claimed |
| CN-102741256-A | Bicyclic heteroaryl derivatives having inhibitory activity for protein kinase | HANMI PHARM IND CO LTD | 2012-10-17 | — | — | CN | claimed |
| US-20090186867-A1 | Substituted Diketopiperazines As Oxytocin Antagonists | GLAXO GROUP LIMITED | 2009-07-23 | — | — | US | claimed |
| US-7514437-B2 | Substituted diketopiperazines as oxytocin antagonists | SMITHKLINE BEECHAM CORP. (US) | 2009-04-07 | — | — | US | claimed |
| EP-1458393-B1 | SUBSTITUTED DIKETOPIPERAZINES AS OXYTOCIN ANTAGONISTS | GLAXO GROUP LTD (GB) | 2008-06-25 | — | — | EP | claimed |
| US-20050148572-A1 | Substituted diketopiperazines as oxytocin antagonists | GLAXO GROUP LIMITED (GB) | 2005-07-07 | — | — | US | claimed |
| WO-2005000311-A1 | SUBSTITUTED DIKETOPIPERAZINES FOR THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA | GLAXO GROUP LIMITED (GB) | 2005-01-06 | — | — | WO | claimed |
| EP-1458393-A1 | SUBSTITUTED DIKETOPIPERAZINES AS OXYTOCIN ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2004-09-22 | — | — | EP | claimed |
| WO-2003053443-A1 | SUBSTITUTED DIKETOPIPERAZINES AS OXYTOCIN ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2003-07-03 | — | — | WO | claimed |
| EP-0171037-A2 | 3-Carbonyl-1-aminoalkyl-1H-indoles useful as analgesics and preparation thereof | STERLING WINTHROP INC. (US) | 1986-02-12 | — | — | EP | claimed |
| EP-3856348-B1 | PYRAZOLO[4,3-D]PYRIMIDINE COMPOUNDS AS ALK2 AND/OR FGFR MODULATORS | INCYTE CORP (US) | 2024-01-03 | — | — | EP | disclosed |
| EP-0171037-A2 | 3-Carbonyl-1-aminoalkyl-1H-indoles useful as analgesics and preparation thereof | STERLING WINTHROP INC. (US) | 1986-02-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050148572-A1 | Substituted diketopiperazines as oxytocin antagonists | OXTR, AVPR2, AVPR1B | L3MBTL3 2574/4885L3MBTL1 2352/4885AR 571/4885 |
| US-20180265467-A1 | PYRAZOLIDINE DERIVATIVES AND RELATED COMPOUNDS | LDHB, LDHA, PDK1 | L3MBTL3 3887/4885L3MBTL1 3923/4885AR 3370/4885 |
| US-20220389009-A1 | SUBSTITUTED 1,6-NAPHTHYRIDINE INHIBITORS OF CDK5 | CDK5, CDK5R1, PKD1 | L3MBTL3 3272/4885L3MBTL1 2207/4885AR 3083/4885 |
| US-20160222014-A1 | COMPOUNDS FOR REGULATING FAK AND/OR SRC PATHWAYS | SRC, PTK2, FYN | L3MBTL3 3296/4885L3MBTL1 3251/4885AR 814/4885 |
| US-20090186867-A1 | Substituted Diketopiperazines As Oxytocin Antagonists | OXTR, AVPR2, CRH | L3MBTL3 3464/4885L3MBTL1 3463/4885AR 774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.